KA Overview

Kineta, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering and developing differentiated immunotherapies that address the challenges with current cancer therapy. Its innate immunity development platform aimed at developing human antibodies to address the mechanisms of cancer immune resistance, such as immuno-suppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of assets and research interests includes KVA12123, a monoclonal antibody (mAb), immunotherapy targeting V-domain Ig suppressor of T cell activation (VISTA), an anti-CD27 agonist mAb immunotherapy and an anti-CD24 antagonist mAb immunotherapy discovery program. VISTA blocks immunotherapy to address the problem of immunosuppression in the tumor microenvironment. It is developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells in the tumor microenvironment. KVA12123 are primarily focused on solid tumors with high levels of VISTA expression.

Wall Street analysts forecast KA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Kineta Inc revenue for the last quarter amounts to 0.00 USD, decreased -100.00

Kineta Inc. EPS for the last quarter amounts to -0.20 USD, decreased -600.00

Kineta Inc (KA) has 11 emplpoyees as of June 04 2026.

Today KA has the market capitalization of 6.99M USD.